Literature DB >> 28791627

Influence of intravenous administration of the antipsychotic drug benperidol on the QT interval.

Alexander Schmidt1, Peter Fischer2, Beate Wally2, Joachim Scharfetter2.   

Abstract

A group effect is generally assumed regarding the prolongation of the QT interval through butyrophenone antipsychotics like haloperidol. Consequently intravenous administration of benperidol is seen critically notwithstanding sparse evidence; thus benperidol and haloperidol were compared regarding their cardiac risk of prolonging the QT interval when administered intravenously for acute sedation of psychotic patients. The QT interval was measured by a 12-lead ECG. For the correction of QT values Bazett's formula was used. The resulting QTc intervals of the benperidol and the haloperidol group were compared using Mann-Whitney U-test. Our data provide statistical evidence for benperidol being less prone to cause QTc prolongation than haloperidol (p = 0.049). The results of our study indicate a more favourable risk profile of benperidol compared to haloperidol regarding QTc prolongation when administered intravenously.

Entities:  

Keywords:  Acute sedation; Haloperidol; IM; IV; QTc

Mesh:

Substances:

Year:  2017        PMID: 28791627     DOI: 10.1007/s40211-017-0230-5

Source DB:  PubMed          Journal:  Neuropsychiatr        ISSN: 0948-6259


  12 in total

1.  A Randomized Controlled Trial of Intravenous Haloperidol vs. Intravenous Metoclopramide for Acute Migraine Therapy in the Emergency Department.

Authors:  Matthew E Gaffigan; David I Bruner; Courtney Wason; Amy Pritchard; Kenneth Frumkin
Journal:  J Emerg Med       Date:  2015-06-02       Impact factor: 1.484

2.  [QTc prolongation induced by intravenous sedation with Haloperidol, Prothipendyl and Lorazepam].

Authors:  Joachim Scharfetter; Peter Fischer
Journal:  Neuropsychiatr       Date:  2014-02-07

3.  Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.

Authors:  Alexander N Katchman; John Koerner; Toshimasa Tosaka; Raymond L Woosley; Steven N Ebert
Journal:  J Pharmacol Exp Ther       Date:  2005-11-08       Impact factor: 4.030

Review 4.  The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?

Authors:  Carla Meyer-Massetti; Christine M Cheng; Bradley A Sharpe; Christoph R Meier; B Joseph Guglielmo
Journal:  J Hosp Med       Date:  2010-04       Impact factor: 2.960

Review 5.  [Pharmacotherapy of psychiatric acute and emergency situations: General principles].

Authors:  T Messer; F-G Pajonk; M J Müller
Journal:  Nervenarzt       Date:  2015-09       Impact factor: 1.214

6.  Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.

Authors:  M L De Bruin; M Pettersson; R H B Meyboom; A W Hoes; H G M Leufkens
Journal:  Eur Heart J       Date:  2005-01-06       Impact factor: 29.983

Review 7.  The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.

Authors:  P Baumann; C Hiemke; S Ulrich; G Eckermann; I Gaertner; M Gerlach; H-J Kuss; G Laux; B Müller-Oerlinghausen; M L Rao; P Riederer; G Zernig
Journal:  Pharmacopsychiatry       Date:  2004-11       Impact factor: 5.788

8.  Comparative evaluation of hERG potassium channel blockade by antipsychotics.

Authors:  J S Silvestre; J R Prous
Journal:  Methods Find Exp Clin Pharmacol       Date:  2007-09

Review 9.  Drug-induced QT interval prolongation: mechanisms and clinical management.

Authors:  Senthil Nachimuthu; Manish D Assar; Jeffrey M Schussler
Journal:  Ther Adv Drug Saf       Date:  2012-10

10.  Antipsychotics and the risk of sudden cardiac death.

Authors:  Sabine M J M Straus; Gysèle S Bleumink; Jeanne P Dieleman; Johan van der Lei; Geert W 't Jong; J Herre Kingma; Miriam C J M Sturkenboom; Bruno H C Stricker
Journal:  Arch Intern Med       Date:  2004-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.